Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS · Delayed Price · Currency is USD
0.0890
+0.0150 (20.27%)
Sep 4, 2026, 4:00 PM EST

Inhibitor Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
13810163756
Market Cap Growth
68.79%-25.02%-34.56%-57.47%-34.06%332.17%
Enterprise Value
125464261
Last Close Price
0.070.040.060.090.100.15

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----3.12-
PB Ratio
-5.03-6.015.223.004.49-15.59
P/TBV Ratio
--5.223.004.49-
P/OCF Ratio
----3.17-

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
-0.02-0.05--0.05-0.06
Net Debt / Equity Ratio
0.181.79-2.82-1.67-1.39-0.05
Quick Ratio
2.953.107.9013.2917.610.05
Current Ratio
3.363.198.0313.4517.640.09
Return on Equity (ROE)
--952.30%-91.88%-44.57%517.86%-
Return on Assets (ROA)
-92.70%-52.20%-31.22%-20.34%-6.83%-213.47%
Return on Capital Employed (ROCE)
-729.10%-196.40%-73.40%-41.10%-5.80%52.40%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-25.70%-42.50%-32.24%-19.12%32.53%-0.53%
Buyback Yield / Dilution
-0.22%-0.14%-0.18%53.04%2.67%-1.16%